Evan Y. Yu

Active 2001–2026

Also published as
Evan Y Yu
152
Papers
25,001
Citations
61
h-index
137
i10-index

Citations

Citations per year for Evan Y. Yu1984: 1 citations1994: 1 citations2001: 3 citations2002: 13 citations2003: 21 citations2004: 55 citations2005: 47 citations2006: 41 citations2007: 31 citations2008: 29 citations2009: 30 citations2010: 52 citations2011: 89 citations2012: 69 citations2013: 106 citations2014: 135 citations2015: 181 citations2016: 236 citations2017: 319 citations2018: 390 citations2019: 921 citations2020: 1,253 citations2021: 1,260 citations2022: 1,081 citations2023: 799 citations2024: 1,326 citations2025: 596 citations2026: 21 citations1985–1993: no citations, so these years are not shown1995–2000: no citations, so these years are not shown

Citation sources

Countries

World map of the countries and regions citing this authorUnited States: 3,875 citing papers, 27.7% of this breakdownChina: 1,327 citing papers, 9.5% of this breakdownUnited Kingdom: 910 citing papers, 6.5% of this breakdownItaly: 731 citing papers, 5.2% of this breakdownCanada: 677 citing papers, 4.9% of this breakdownGermany: 613 citing papers, 4.4% of this breakdownFrance: 565 citing papers, 4% of this breakdownSpain: 486 citing papers, 3.5% of this breakdownJapan: 417 citing papers, 3% of this breakdownNetherlands: 383 citing papers, 2.7% of this breakdownAustralia: 370 citing papers, 2.7% of this breakdownSwitzerland: 331 citing papers, 2.4% of this breakdown
0%27.7%Other 23.5%

Fields

  • Medicine65.2%
  • Biochemistry, Genetics and Molecular Biology28.9%
  • Immunology and Microbiology2.9%
  • Neuroscience0.7%
  • Agricultural and Biological Sciences0.4%
  • Engineering0.4%
  • Other1.5%

Topics

  • Prostate Cancer Treatment and Research11.4%
  • Cancer Immunotherapy and Biomarkers5%
  • Prostate Cancer Diagnosis and Treatment4.7%
  • Bladder and Urothelial Cancer Treatments4.5%
  • Extracellular vesicles in disease2.9%
  • Cancer Genomics and Diagnostics2.4%
  • Other69.1%

Coauthors

All papers

Open in search
  1. Integrative Clinical Genomics of Advanced Prostate Cancer

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Victor E. Reuter, Anuradha Gopalan, Jianjiong Gao, Massimo Loda, Rosina T. Lis, Michaela Bowden, Stephen Balk, Glenn C. Gaviola, Carrie Sougnez, Manaswi Gupta, Evan Y. Yu, Elahe A. Mostaghel, Heather H. Cheng, Hyojeong Mulcahy, Lawrence D. True, Stephen R. Plymate, Heidi Dvinge, Roberta Ferraldeschi, Penny Flohr, Susana Miranda, Zafeiris Zafeiriou, Nina Tunariu, Joaquı́n Mateo, Raquel Pérez-López, Francesca Demichelis, Brian D. Robinson, Marc Schiffman, David M. Nanus, Scott T. Tagawa, Alexandros Sigaras, Kenneth Eng, Olivier Elemento, Andrea Sboner, Elisabeth I. Heath, Howard I. Scher, Kenneth J. Pienta, Philip W. Kantoff, Johann S. de Bono, Mark A. Rubin, Peter S. Nelson, Levi A. Garraway, Charles L. Sawyers, Arul M. Chinnaiyan - Cell 2015 cited by 3,701

  2. Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Sanjeev Mariathasan, AnnChristine Thåström, Oyewale O. Abidoye, Gregg Fine, Dean F. Bajorin - The Lancet 2016 cited by 2,211

  3. Pembrolizumab alone or combined with chemotherapy versus chemotherapy as first-line therapy for advanced urothelial carcinoma (KEYNOTE-361): a randomised, open-label, phase 3 trial

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Brieuc Sautois, Jean‐Pascal Machiels, Denis Schallier, Leandro Brust, Liane Rapatoni, Sérgio Jobim Azevedo, GISELE LOPES MARINHO, João Paulo Holanda Soares, Carlos Dzik, Jamile Almeida Silva, André P. Fay, Joel Gingerich, Yves Fradet, Cristiano Ferrario, Kylea Potvin, Marie Vanhuyse, Mahmoud Abdelsalam, Susanna Cheng, Christian Caglevic, Felipe Reyes, José Luis Leal, Francisco Francisco, Carolina Ibáñez, Florence Joly, Brigitte Laguerre, Sylvain Ladoire, Aude Fléchon, Delphine Topart, Olivier Huillard, Stéphane Oudard, Marine Gross‐Goupil, Stéphane Culine, Yohann Loriot, Gwénaëlle Gravis, Peter Reichardt, Margitta Retz, Jan Herden, David G. Pfister, Carsten Ohlman, Michael Stöeckle, Manfred P. Wirth, Anja Lorch, Guenter Niegisch, Peter J. Goebell, Martin Boegemann, Axel S. Merseburger, Georgios Gakis, Jens Bedke, Andreas Neisius, Christian A. Thomas, Thomas Hoefner, András Telekes, Judit Kósa, János Révész, Gyorgy Bodoky, Tibor Csőszi, András Csejtei, Lajos Géczi, Ágnes Ruzsa, Zsuzsanna Kolonics, József Erfán, Ray McDermott, Richard Bambury, Avishay Sella, Stephen Jay Frank, Daniel Kejzman, Olesya Goldman, Eli Rosenbaum, Avivit Peer, Raanan Berger and 158 more - The Lancet Oncology 2021 cited by 648

  4. Lentivirus-delivered stable gene silencing by RNAi in primary cells

    Authors: , , , , , , , , , , , - RNA 2003 cited by 1,646

  5. Pivotal Trial of Enfortumab Vedotin in Urothelial Carcinoma After Platinum and Anti-Programmed Death 1/Programmed Death Ligand 1 Therapy

    Authors: , , , , , , , , , , , , - Journal of Clinical Oncology 2019 cited by 626

  6. Quantitative and stoichiometric analysis of the microRNA content of exosomes

    Authors: , , , , , , , , , , , , , , , , - National Academy of Sciences, Proceedings of the National Academy of Sciences 2014 cited by 1,095

  7. Abiraterone in Metastatic Prostate Cancer without Previous Chemotherapy

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Thomas W. Griffin, Howard I. Scher, Dana E. Rathkopf - New England Journal of Medicine 2012 cited by 2,795

  8. Molecular profiling stratifies diverse phenotypes of treatment-refractory metastatic castration-resistant prostate cancer

    Authors: , , , , , , , , , , , , , , , , , , , , , - Journal of Clinical Investigation 2019 cited by 468

  9. The Role of Lineage Plasticity in Prostate Cancer Therapy Resistance

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , William L. Dahut, Peter S. Nelson - Clinical Cancer Research 2019 cited by 394

  10. Enfortumab vedotin after PD-1 or PD-L1 inhibitors in cisplatin-ineligible patients with advanced urothelial carcinoma (EV‑201): a multicentre, single-arm, phase 2 trial

    Authors: , , , , , , , , , , , , , , , , , , , - The Lancet Oncology 2021 cited by 267

  11. Substantial interindividual and limited intraindividual genomic diversity among tumors from men with metastatic prostate cancer

    Authors: , , , , , , , , , , , , , , , , , , , , , , - Nature Medicine 2016 cited by 763

  12. Pembrolizumab Plus Olaparib for Patients With Previously Treated and Biomarker-Unselected Metastatic Castration-Resistant Prostate Cancer: The Randomized, Open-Label, Phase III KEYLYNK-010 Trial

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Evan Y. Yu - Journal of Clinical Oncology 2023 cited by 132

  13. Niraparib in patients with metastatic castration-resistant prostate cancer and DNA repair gene defects (GALAHAD): a multicentre, open-label, phase 2 trial

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Peter Schatteman, Nicolaas Lumen, Luc Dirix, Jean-Charles Goeminne, Thierry Gil, Emmanuel Seront, Christof Vulsteke, Celio Kussumoto, Fabio A. Franke, Fabricio Augusto Martinelli de Oliveira, Andrea Juliana Pereira de Santana Gomes, Hélio Pinczowski, Daniel D'Almeida Preto, Luis Eduardo Zucca, Giuliano Santos Borges, Andre M. Murad, Fred Saad, Kim N. Chi, Yves Fradet, Neil E. Fleshner, Urban Emmenegger, Klaus Brasso, Karim Fizazi, Stephane Culine, Antoine Thiery-Vuillemin, Florence Joly, Aude Fléchon, Werner Hilgers, Jean-Christophe Eymard, Delphine Borchiellini, Philippe Barthélémy, Raanan Berger, Raya Leibowitz-Amit, Wilmosh Mermershtain, Keren Rouvinov, Avivit Peer, Svetlana Kovel, Avishay Sella, Martijn P. Lolkema, Alfonsus J.M. van den Eertwegh, Johannes Voortman, Maureen J. Aarts, Jourik A. Gietema, Choung-Soo Kim, Young-Deuk Choi, Byung-Ha Chung, Rustem A. Gafanov, Evgeniy Kopyltsov, Evgeny A. Usynin, Joan Carles, Begoña Mellado, José Pablo Maroto, Jesús García-Donás, Juan Francisco Rodríguez Moreno, Ignacio Durán, Begoña Pérez-Valderrama, Elena Castro, David Olmos, María José Méndez-Vidal, David Lorente Estellés, Regina Gironés Sarrió, José Muñoz-Langa, Urbano Anido Herranz, Javier Puente Vázquez, Enrique Castellanos, Martin Hellström, Anders Widmark, Ingela Franck Lissbrant, Åsa Jellvert, Cecilia Külich and 34 more - The Lancet Oncology 2022 cited by 186

  14. Tucatinib and Trastuzumab for Previously Treated Human Epidermal Growth Factor Receptor 2–Positive Metastatic Biliary Tract Cancer (SGNTUC-019): A Phase II Basket Study

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , - Journal of Clinical Oncology 2023 cited by 100

  15. Association of Clonal Hematopoiesis in DNA Repair Genes With Prostate Cancer Plasma Cell-free DNA Testing Interference

    Authors: , , , , , , , , , , , - JAMA Oncology 2020 cited by 158

  16. Integrative Clinical Genomics of Advanced Prostate Cancer

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Victor E. Reuter, Anuradha Gopalan, Jianjiong Gao, Massimo Loda, Rosina T. Lis, Michaela Bowden, Stephen Balk, Glenn C. Gaviola, Carrie Sougnez, Manaswi Gupta, Evan Y. Yu, Elahe A. Mostaghel, Heather H. Cheng, Hyojeong Mulcahy, Lawrence D. True, Stephen R. Plymate, Heidi Dvinge, Roberta Ferraldeschi, Penny Flohr, Susana Miranda, Zafeiris Zafeiriou, Nina Tunariu, Joaquı́n Mateo, Raquel Pérez-López, Francesca Demichelis, Brian D. Robinson, Andrea Sboner, Marc Schiffman, David M. Nanus, Scott T. Tagawa, Alexandros Sigaras, Kenneth Eng, Olivier Elemento, Andrea Sboner, Elisabeth I. Heath, Howard I. Scher, Kenneth J. Pienta, Philip W. Kantoff, Johann S. de Bono, Mark A. Rubin, Peter S. Nelson, Levi A. Garraway, Charles L. Sawyers, Arul M. Chinnaiyan - Cell 2015 cited by 591

  17. Implementation of Germline Testing for Prostate Cancer: Philadelphia Prostate Cancer Consensus Conference 2019

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Jacqueline Powers, Raoul S. Concepcion, Daniel W. Lin, Richard C. Wender, James Ryan Mark, Anthony J. Costello, Arthur L. Burnett, Oliver Sartor, William B. Isaacs, Jianfeng Xu, Jeffrey N. Weitzel, Gerald L. Andriole, Himisha Beltran, Alberto Briganti, Lindsey Byrne, Anne Calvaresi, Thenappan Chandrasekar, David Y.T. Chen, Robert B. Den, Albert Dobi, E. David Crawford, James A. Eastham, Scott E. Eggener, Matthew L. Freedman, Marc B. Garnick, Patrick T. Gomella, Nathan Handley, Mark Hurwitz, Joseph K. Izes, R. Jeffrey Karnes, Costas D. Lallas, Lucia R. Languino, Stacy Loeb, Ana María López, Kevin R. Loughlin, Grace Lu‐Yao, S. Bruce Malkowicz, Mark Mann, Patrick Mille, Martin Miner, Todd M. Morgan, José Moreno, Lorelei A. Mucci, Ronald E. Myers, Sarah M. Nielsen, Brock O’Neil, Wayne H. Pinover, Peter A. Pinto, Wendy Poage, Ganesh V. Raj, Timothy R. Rebbeck, Charles J. Ryan, Howard M. Sandler, Matthew J. Schiewer, Emily Scott, Brittany M. Szymaniak, William Tester, Edouard J. Trabulsi, Neha Vapiwala, Evan Y. Yu, Charnita Zeigler‐Johnson, Leonard G. Gomella - Journal of Clinical Oncology 2020 cited by 279

  18. Primary analysis from DS8201-A-U105: A phase 1b, two-part, open-label study of trastuzumab deruxtecan (T-DXd) with nivolumab (nivo) in patients (pts) with HER2-expressing urothelial carcinoma (UC).

    Authors: , , , , , , , , , , , , , , , , , , , - Journal of Clinical Oncology 2022 cited by 85

  19. Pembrolizumab Plus Docetaxel and Prednisone in Patients with Metastatic Castration-resistant Prostate Cancer: Long-term Results from the Phase 1b/2 KEYNOTE-365 Cohort B Study

    Authors: , , , , , , , , , , , , , , , , , , , , , - European Urology 2022 cited by 79

  20. IL-7 expands lymphocyte populations and enhances immune responses to sipuleucel-T in patients with metastatic castration-resistant prostate cancer (mCRPC)

    Authors: , , , , , , , , , , , , , , , , , , , , , , - Journal for ImmunoTherapy of Cancer 2021 cited by 67

  21. Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1–2 study

    Authors: , , , , , , , , , , , , , , , , , , - The Lancet 2010 cited by 1,084

  22. Disparities in Cancer Care and the Asian American Population

    Authors: , , , , - The Oncologist 2021 cited by 141

  23. A phase I study of niclosamide in combination with enzalutamide in men with castration-resistant prostate cancer

    Authors: , , , , , , , , , , , - PLoS ONE 2018 cited by 137

  24. Genome-wide genotype-serum proteome mapping provides insights into the cross-ancestry differences in cardiometabolic disease susceptibility

    Authors: , , , , , , , , , , , , , , , , , , , , , , , - Nature Communications 2023 cited by 60